Volume 22, Issue 6 (Iranian South Medical Journal 2020)                   Iran South Med J 2020, 22(6): 371-380 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Cheraghi F, Zargar M, Bolkheir A. Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital. Iran South Med J 2020; 22 (6) :371-380
URL: http://ismj.bpums.ac.ir/article-1-1199-en.html
Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital
Fatemeh Cheraghi1 , Mahvash Zargar1 , AmirReza Bolkheir * 2
1- Department of Obstetrics and Gynecology, School of Medicine, Jondishapoor University of medical science, Ahvaz, Iran
2- Department of Obstetrics and Gynecology, School of Medicine, Jondishapoor University of medical science, Ahvaz, Iran , bolkhayramirreza@yahoo.com
Abstract:   (3277 Views)
 
Background: Given that ovarian cancer symptoms are nonspecific and that appropriate surgical staging and pathological grading are important for the best treatment and prognosis of patients, this study aimed to determine the correlation of preoperative serum levels of CA125 and He4 with staging and grading.
Materials and Methods: This cross-sectional study recruited 29 patients with epithelial ovarian cancer who underwent staging based on FIGO protocol and grading by pathologist during 2011-13. Serum CA125 and He4 were determined preoperatively to measure the correlation of these tumor markers with staging and grading.
Results: We did not observe a significant correlation between preoperative serum levels of CA125 and He4, and ovarian epithelial cancer staging and grading (P>0.05). However, serum levels of CA125 and He4 were significantly correlated with each other (P>0.001).
Conclusion: Based on this study, we cannot differentiate epithelial ovarian cancer surgical staging or pathological grading by preoperative CA125 and He4 serum levels.  
 
Keywords: Ovarian epithelial cancer, Surgical staging, He4, CA125.
Full-Text [PDF 592 kb]   (1115 Downloads)    
Type of Study: Original | Subject: Gynecology
Received: 2019/09/23 | Accepted: 2019/12/1 | Published: 2020/01/28
References
1. Arab M, Khayamzadeh M, Tehranian A, et al. Incidence Rate of Ovarian Cancer in Iran in Comparison with Developed Countries. Indian J Cancer 2010; 47(3): 322-7. [DOI:10.4103/0019-509X.64721]
2. Khodabakhshi R, Yahyazadeh-Jabbari SH, Gohari MR, et al . Treatment and prognosis of epithelial ovarian cancer: five year multi-center study. Saudi Med J 2008 Dec;29(12):1735-8.
3. Ren J, Cai H, Li Y, et al. Tumor Markers for Early Detection of Ovarian Cancer. Expert Rev Mol Diagn 2010; 10(6): 787-98. [DOI:10.1586/erm.10.39]
4. Gibbs RS, Karlan BY, Haney AF, et al. Ovarian and Fallopian Tube Cancers, Danforth's Obstetrics and Gynecology. 10th ed. Philadelphia: Lippincot, Williams & Wilkins, 2008, 1136.
5. Bast RC, Badgwell D, Lu Z, et al. New Tumor Markers: CA125 and Beyond. Int J Gynecol Cancer 2005; 15(S3): 274-81. [DOI:10.1111/j.1525-1438.2005.00441.x]
6. Woolas RP, Xu FJ, Jacabs IJ, et al. Elevation of Multiple Serum Markers in Patients with Stage I Ovarian Cancer. J Natl Cancer Inst 1993; 85(21): 1748-51. [DOI:10.1093/jnci/85.21.1748]
7. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum Biomarker Panels for the Discrimination of Benign from Malignant Cases in Patients with an Adnexal Mass. Gynecol Oncol 2010; 117(3): 440-5. [DOI:10.1016/j.ygyno.2010.02.005]
8. Moore RG, Brown AK, Miller MC, et al. The Use of Multiple Novel Tumor Biomarkers for the Detection of Ovarian Carcinoma in Patients with a Pelvic Mass. Gynecol Oncol 2008; 108(2): 402-8. [DOI:10.1016/j.ygyno.2007.10.017]
9. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Cancer. Cancer Res 2000; 60(22): 6281-7.
10. Schummer M, Ng WV, Bumgarner RE, et al. Comparative Hybridization of an Array of 21,500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas. Gene 1999; 238(2): 375-85. [DOI:10.1016/S0378-1119(99)00342-X]
11. Paek J, Lee SH, Yim GW, et al. Prognostic Significance of Human Epididymis Protein 4 in Epithelial Ovarian Cancer. Eur J Obstet Gynecol Reprod Biol 2011; 158(2): 338-42. [DOI:10.1016/j.ejogrb.2011.05.021]
12. Moore RG, Miller CM, Brown AK, et al. Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus. Int J Gynecol Cancer 2011; 21(7): 1185-90. [DOI:10.1097/IGC.0b013e3182229ad8]
13. Kristjansdottir B, Levan K, Partheen K, et al. Diagnostic Performance of the Biomarkers HE4 and CA125 in Type I and Type II Epithelial Ovarian Cancer. Gynecol Oncol 2013; 131(1): 52-8. [DOI:10.1016/j.ygyno.2013.07.094]
14. Zhen S, Bian LH, Chang LL, et al. Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Ovarian Cancer: A Meta‑ Analysis. Mol Clin Oncol 2014; 2(4): 559-66. [DOI:10.3892/mco.2014.279]
15. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) Protein is A Biomarker for Ovarian Carcinoma. Cancer Res 2003; 63(13): 3695-700.
16. Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, et al. Differentiating Stage 1 Epithelial Ovarian Cancer from Benign Ovarian Tumours Using A Combination of Tumour Markers HE4, CA125, and CEA and Patient's Age. Gynecol Oncol 2013; 129(3): 467-71. [DOI:10.1016/j.ygyno.2013.03.001]
17. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of A Multimarker Assay for Early Detection of Ovarian Cancer. J Clin Oncol 2010; 28(13): 2159-66. [DOI:10.1200/JCO.2008.19.2484]
18. Zhu YF, He LS, Zhang ZD, et al. Expression of Serum Human Epididymal Secretory Protein E4 at Low Grade and High Grade Serous Carcinomas. Asian Pac J Trop Med 2012; 5(12): 925-30. [DOI:10.1016/S1995-7645(12)60175-8]
19. Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and Mesothelin: Novel Biomarkers of Ovarian Carcinoma in Patients with Pelvic Masses. Asian Pac J Cancer Prev 2010; 11(1): 111-6.
20. Park Y, Lee JH, Hong DJ, et al. Diagnostic Performances of HE4 and CA125 for the Detection of Ovarian Cancer from Patients with Various Gynecologic and Non-Gynecologic Diseases. Clin Biochem 2011; 44(10-11): 884-8. [DOI:10.1016/j.clinbiochem.2011.04.011]
21. Lawicki S, Będkowska GE, Gacuta-Szumarska E, et al. The Plasma Concentration of VEGF, HE4 and CA125 as A New Biomarkers Panel in Different Stages and Sub-Types of Epithelial Ovarian Tumors. J Ovarian Res 2013; 6(1): 45. [DOI:10.1186/1757-2215-6-45]
Send email to the article author

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian South Medical Journal

Designed & Developed by: Yektaweb